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Belgian Working Group on Invasive Cardiology, Mayo Clinic PCI Registry, and Scottish Coronary
Revascularisation Registry Glasgow, United Kingdom; Rochester, MN; Calgary, Canada; and Liege,
and Gent, BelgiumObjective We aimed to analyze trends in drug-eluting stents (DES) use in four international health care and
regulatory settings.
Background Accounts suggest a differential approach to DES internationally and recent reductions in use following
reports of late stent thrombosis. Current studies of clinical practice are limited in their scope.
Methods Data were pooled from angioplasty registries in Alberta (Canada), Belgium, Mayo Clinic (Rochester, MN), and
Scotland (UK) that have routinely recorded consecutive patients treated since 2003. Trend analysis was performed to examine
variations in DES use over time and by clinical subgroup.
Results A total of 178,504 lesions treated between January 2003 and September 2007 were included. In the Mayo
Clinic Registry, rapid adoption to a peak of 91% DES use for all lesions by late 2004 was observed. In contrast, Alberta and
Scotland showed delayed adoption with lower peak DES use, respectively, 56% and 58% of lesions by early 2006. Adoption
of DES in Belgium was more gradual and peak use of 35% lower than other registries. Reductions in DES use were seen in all
data sets during 2006, although this varied in absolute and relative terms and by clinical subgroup.
Conclusion Adoption and use of DES showed wide variation in four countries. The determinants of use are complex, and
it is likely that nonclinical factors predominate. Recent reductions in use may be as a consequence of publicity and concerns
regarding late stent thrombosis. The optimum application of DES in clinical practice is unclear and is reflected in the degree of
international variation demonstrated. (Am Heart J 2009;158:576-84.)Drug-eluting stents (DES) are proven to reduce rest-
enosis in selected populations compared with bare metal
stents (BMS).1-4 Consequently, they were licensed for use
across Europe and North America. Despite their estab-
lished effectiveness in randomized controlled trials, the
clinical and cost effectiveness of unrestricted DES use in
routine practice has since been debated.5-8 Given the
financial consequences of widespread use of these more
expensive stents, some health care systems introduced
guidelines or encouraged restricted indications for DES
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doi:10.1016/j.ahj.2009.07.033Against this background, abstracts presented at the
World Congress of Cardiology (WCC) in September 2006
brought into question the safety of DES and, in particular,
the complication of late stent thrombosis.13-17 Anecdotal
accounts suggest a differential approach to DES use
internationally and reductions in use following the issue
of late stent thrombosis. Previous studies have examined
the uptake of DES within single health care systems or
analyzed the impact of DES on patient selection for
percutaneous coronary intervention (PCI) versus coro-
nary artery bypass grafting.18-20 However, there are
limited patient-level analyses of international practice.
This study aimed to show whether the adoption and use
of DES varied internationally, and how the stent
thrombosis controversy has affected practice.Methods
Data sources and patient populations
This study involved collaboration between centers from four
countries that have established large regional or national PCI data
sets of consecutive patients treated in routine clinical practice.
The data sets included were the APPROACH Registry (Alberta,







population Data collection DES licensing
APPROACH Alberta, Canada 1995 3 3.5 million All patients, prospective SES: November 2002
PES: September 2003
BWGIC Belgium 2003 32 10.4 million All patients, prospective SES: April 2002
PES: January 2003




Scotland, UK 1997 7 5.1 million All patients, prospective SES: April 2002
PES: January 2003
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Volume 158, Number 4Canada), BWGIC Registry, Mayo Clinic PCI Registry (Rochester,
MN), and the Scottish Coronary Revascularisation Registry
(Scotland, UK) (Table I). In each registry, data collection and
entry is prospective and performed by a combination of
administrative and clinical staff. All data were stripped of unique
patient identifiers. Data extracts were obtained from the
APPROACH registry, Mayo Clinic PCI registry, and Scottish
Revascularisation Registry for all consecutive patients undergo-
ing successful PCI from January 2003 to September 2007
inclusive. Belgian data were available from November 2003 to
September 2007. Changes in the collection method for the
Belgian registry (introduced in October 2005) resulted in those
data only being used for some of the study analyses.
Variables and definitions
Data fields obtained included patient-level demographic
details, diabetic status, indication for PCI, and lesion-level
angiographic details including type of intervention, type of
stent, treated vessel, and stent dimensions. Diabetes mellitus
was defined as either type 1 or type 2 diabetes mellitus treated
with insulin or oral hypoglycemic agents. Clinical presentation
was recorded as the principal indication for PCI. Stent diameter
was the maximum diameter stent successfully deployed within
each lesion, and lesion length was the total length stented.
Statistical analysis
The unit of analysis was the lesion. We defined the binary
outcome for each lesion as treatment with either DES or BMS.
Patients who did not receive a stent were excluded from the
analysis. Case mix at baseline was summarized for each registry.
Patient and lesion level variables are presented in relation to
their respective denominators. Variables are reported as number
(percentage) for categorical data, mean (SD) for normally
distributed data, and median (interquartile range) for skewed
data. Data were compared between countries using one-way
analysis of variance (normal distribution), Kruskall-Wallis test
(skewed or ordinal data) or χ2 test (categorical data).The date of
each procedure was recorded to the level of calendar month.
The overall percentage of patients treated with a DES was
calculated by country or region over the period of overlap
between the US, Canadian, and Scottish registries (January 2003-
September 2007). Corresponding data from the Belgian registry
were available since November 2003 for overall analysis and
October 2005 for diabetic and clinical indication sub-groups.
To present the data, local likelihood-based, nonparametric
logistic regression estimates21 of the trends in percentage DESuse were calculated by country and shown graphically with 95%
CIs. The SD of the normal kernel function used was chosen to be
4 months (120 days), based on a visual inspection of figures
using a range of alternative parameters. First, an overall
unadjusted time trend by country model was constructed.
Figures were then produced in a similar fashion for subsets of
data: vessel dimensions (≥3/b18, ≥3/≥18, b3/b18 and b3/≥18
mm), diabetes, and ST-elevation myocardial infarction (STEMI).
Finally, to assess the possible effect of case mix differences
between countries, a Generalized Additive Regression model
was used to estimate the time trends in DES use by country. This
model was adjusted for age, sex, clinical presentation, diabetic
status, vessel diameter and lesion length. Smoothing analyses
were performed using the “sm” package (v2.1) within R for
Windows v2.7.0,22 and the adjusted model constructed using
the “mgcv” package (v1.3-30), with the nonlinear time trend
modeled using cubic splines. No extramural funding was used to
support this work. The authors are solely responsible for the
design and conduct of this study, all study analyses, the drafting
and editing of the manuscript, and its final contents
Results
Baseline characteristics
All consecutive lesions treated with a stent during the
study period were included in the overall analysis. In
total, 178,504 stented lesions in the four geographical
areas were included in the overall comparison. For the
analyses by diabetic and clinical indication subgroup,
118,827 lesions were included from the four registries.
For analyses by lesion dimension and the adjusted model,
68,781 lesions were included from the APPROACH, Mayo
Clinic, and Scottish registries. Procedural volume during
the study was constant within the APPROACH, Mayo
Clinic, and BWGIC Registries but was seen to increase
year-on-year in the Scottish Registry. Case mix for each
registry period is described in Table II. Statistical
differences between registries were identified for clinical
and demographic case mix variables.
Adoption and peak use of drug-eluting stents
The Mayo Clinic PCI Registry demonstrated rapid
adoption of DES into clinical practice (Figures 1-5).
Peak use was observed by February 2005 when 91% of
stented lesions were treated with a DES. Peak use of N89%









Patients 19 515 6 955 23 507 43 759
Age (mean ± SD) 62.7 (11.7) 66.5 (12.3) 61.6 (10.9) 67.3 (12.5) b.001
Male 14 942 (76.4) 4903 (70.5) 16 630 (70.7) 31 682 (72.4) b.001
Diabetes mellitus 4405 (23.1) 1712 (24.8) 3100 (14.1) 8621 (19.7) b.001
Indication for PCI b.001
Stable or
unstable angina
8574 (45.7) 3582 (66.4) 15 444 (67.7) 29 669 (67.8)
Non-STEMI 3849 (20.5) 679 (12.6) 4838 (21.2) 4901 (11.2)




Single vessel 17 845 (87.0) 6013 (86.5) 18 877 (83.0) 40 433 (92.4)
2 Vessels 2318 (11.4) 861 (12.4) 3543 (15.6) 3150 (7.2)
3 Vessels 171 (0.8) 81 (1.1) 317 (1.4) 176 (0.4)
Lesions
Total 27 732 9266 31 783 50 046
2003 5076 1941 5209 –
2004 6153 2078 6154 –
2005 6445 2010 7173 –
2006 5867 2034 7451 29 069
2007⁎ 4191 1203 5796 20 977
Treated vessel
RCA 10 557 (38.2) 2949 (31.8) 11 273 (35.5) – b.001
LCx 6099 (22.1) 2047 (22.1) 7060 (22.2) –
LAD 10 039 (36.3) 3417 (36.9) 12 017 (37.8) –
LMCA 94 (0.3) 188 (2.0) 436 (1.4) –
Bypass graft 538 (1.9) 665 (7.2) 991 (3.1) –
Stented length (mm)
median (IQR) 18 (15-24) 18 (13-23) 18 (15-27) – b.001
b16 mm 8588 (31.2) 3101 (34.6) 9215 (29.0) – b.001
16-30 mm 14 601 (53.1) 4629 (51.7) 15 681 (49.3) –
≥30 mm 4305 (15.7) 1223 (13.7) 5035 (15.8) –
Stent diameter (mm) –
Median (IQR) 3.0 (2.5-3.5) 3.0 (3.0-3.5) 3.0 (2.75-3.5) – b.001
b3 mm 9651 (35.1) 1881 (21.0) 8384 (26.4) – b.001
≥ 3 mm 17 838 (64.9) 7062 (79.0) 21 568 (67.9) –
Probability statistics are derived from 1-way analysis of variance (normal distribution), Kruskall-Wallis test (skewed or ordinal data), or χ2 test (categorical data).
RCA, Right coronary artery; LCx, left circumflex artery; LAD, left anterior descending artery; LMCA, left main coronary artery; IQR, interquartile range.
⁎ January 2003 to September 2007.
† From January 2006 to Sept 2007.
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October 2009was observed in all sub-groups (Figures 2-4). In Alberta,
the unadjusted estimates demonstrated a more gradual
uptake of DES with peak use observed in January 2006 at
56% of lesions (Figure 1). In contrast to Alberta, DES
uptake in Scotland exhibited a prolonged phase of
relatively low utilization before a steeper adoption
curve during 2005. DES use within Scotland peaked at
58% of lesions in March 2006 (Figure 1). At peak use, after
adjustment for case mix, there was no statistical
difference between the UK and Canadian registries
(Figure 5). The lowest and latest peak adoption was
within Belgium, where DES use peaked at 35% of stented
lesions in June 2006 (Figure 1).
Patient selection for drug-eluting stents
In Alberta and Scotland, selection for DES on patient
and lesion characteristics was evident throughout. Atpeak adoption, high levels of DES use in lesions at highest
baseline risk of restenosis (b3/≥18 mm) was observed:
75% in Alberta, 87% in Scotland and 98% at the Mayo
Clinic (Figure 2, D). However, variation between
registries was greater in lesions at moderate risk of
restenosis (N3/≥18, ≤3/b18 mm [Figure 2, B and C]) and
further still for lesions at lowest baseline risk (N3/b18 mm
[Figure 2, A]) due to lower use in Alberta and Scotland
among these subgroups. In Alberta and Scotland,
relatively higher DES use by subgroup was also observed
for diabetic patients (Figure 3). In contrast, lower DES use
was observed for STEMI (Figure 4) in Scotland and
Alberta, but not the Mayo Clinic.
Where Belgian subgroup data were available, they
demonstrated marked differences in use by diabetic
status. DES use among people with diabetes showed no
statistical difference to the Mayo Clinic registry in late
Figure 1
Crude DES use by registry (smooth estimate with 95% CI).
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Volume 158, Number 42006 and was higher than both the Scottish and Canadian
registries (Figure 3). In common with the Scottish and
Canadian registries, relatively lower DES use was
observed for STEMI (Figure 4).
Reductions in drug-eluting stent use
The Mayo Clinic PCI Registry recorded small reduc-
tions in DES use during 2005, followed by a steeper
decline during 2006. From the unadjusted smoothed
trend line, the estimated absolute reduction from peak
DES use was 16%, a relative reduction of 18%. In
comparison with the other registries, DES use remained
statistically higher throughout maintained N74% of
stented lesions (Figures 1 and 5). Differential reductions
in DES use by clinical indication were observed in the US
registry. Reductions in DES use were greater in patients
treated for STEMI (Figure 4), and N3/b18-mm lesions
(Figure 2).
In both Alberta and Scotland, DES use started to decline
in the second quarter of 2006 (Figures 1 and 5). For
Alberta, a 19% absolute reduction and 34% relative
reduction from peak DES use was observed by the end
of the study period. In Scotland, a smaller absolute
reduction of 16%, a relative reduction of 28%, was
observed. In both registries, pre-evident patient selection
remained apparent. In contrast, the BWGIC Registry
showed a 1% absolute and 3% relative reduction in DES
use during 2006 (Figure 1). By the end of the study
period, DES were used in 75% of stented lesions in the
Mayo Clinic, 42% in Scotland, 37% in Alberta and 32% in
Belgium (Figure 1).Discussion
This study of PCI practice in four countries demon-
strated wide variations in the adoption and utilization of
DES. We also established that DES use reduced in all
registries during 2006 and 2007; the timing and extent
of these reductions varied by registry. Marked differ-
ences in use by clinical subgroup were evident
throughout and observations held even after adjustment
for case mix differences.
Adoption and peak use
Variations in adoption and peak use exist despite the
international nature of clinical scientific evidence and the
widespread marketing and availability of DES. In the
Mayo Clinic Registry, increased DES use corresponded
closely with the Food and Drug Administration approval
of the sirolimus-eluting Cypher stent23 (SES, April 2003)
and then paclitaxel-eluting Taxus stent24 (PES, March
2004) and mirror previous descriptions of US adoption
patterns.18 Both across Europe and in Canada, prior
licensing of SES (CE Mark April 2002, Health Canada
approval November 2002) and PES (CE Mark, January
2003, Health Canada approval September 2003) had
occurred. Therefore, the delayed adoption of DES outside
the United States was not related to delayed regulatory
approval in these countries.
Drug-eluting stent use varies at hospital level within
single health care systems.18-20 Influences are thought
to include differences in funding (eg, private/govern-
ment, proportion of patients insured), type of hospital
(eg, academic/non academic, urban/rural), and local
priority setting. Individual interventional cardiologists
also vary in their use of DES, and their rate of
technology adoption.19,25 Furthermore, it is possible
that, in the United States in particular, adoption may
have been partly driven by concerns of medical
malpractice with underuse.26 However, such disparities
in international adoption patterns seem unlikely to be
fully explained by individual clinician preference, local
hospital factors, differing patient selection for PCI over
other treatments (such as coronary artery bypass
grafting or medical therapy), or unaccounted for
clinical factors.
Indeed, the adoption of high cost new technologies are
thought to be sensitive to the stringency of regulation, the
responsiveness of payment systems to changes in
practice (eg, centrally funded, reimbursement, private),
the autonomy of local decision making, and overall levels
of health care funding.27 In this study, we showed rapid
uptake of DES at the Mayo Clinic—a private, not-for-
profit, academic institution within the influence of the US
health care system, where stent choice was at the
discretion of individual operators. As an example here,
there is low regulation, a payment system rapidly
responsive to changes in practice, high local autonomy,
Figure 2
Drug-eluting stent use by registry for lesion dimensions: ≥3/b18 (A), ≥3/≥18 (B), b3/b18 (C), and b3/≥18 mm (D) (smooth estimate with 95% CI).
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October 2009and high levels of health care funding. Such an
environment encourages rapid and high levels of
technology adoption as seen with DES in this study.
As a further illustration, early policy in Belgium was to
only reimburse the full cost of DES to hospitals for use in
diabetic patients.12 The influence of this policy on
practice is clearly demonstrated in this study. In this
case, regulation and payment were strictly controlled,
local autonomy was therefore low, and overall costs were
controlled; the result was slow adoption and low peak
use. A recent health technology assessment in Belgium
has concluded against the extension of DES use in other
clinical indications on cost grounds.12Differential selection for drug-eluting stents
We demonstrated differential selection for DES in
Scotland and Alberta based on patient and lesion
characteristics. In the United Kingdom and Canada,
early cost-effectiveness analyses and health technology
assessments resulted in clinical policies that favoredthe “targeting” of DES to patients felt to be at higher
risk of restenosis.6,9,11,28-30 In both the United
Kingdom and Canada, these recommendations explic-
itly considered cost and were designed to limit overall
use. In the United Kingdom, The National Institute for
Health and Clinical Excellence recommended DES in
non–myocardial infarction patients with lesions N15
mm length and in vessels b3 mm.9,10 Using similar
rationale, the Canadian province of Ontario recom-
mended DES use in diabetic patients, lesions N18 mm,
vessels of ≤2.75 mm, or an otherwise defined high
risk lesion.11
Both UK and Canadian health care systems are largely
publicly funded, although neither employs a system of
direct reimbursement for DES used in recommended
indications. In such health care systems, the interven-
tional cardiologist plays a role in “gate-keeping” to ensure
overall costs are limited and DES are used for those
considered to have the greatest clinical “need.” Our data
demonstrate that such policy has influenced clinical
practice during the period of study.
Figure 3
Drug-eluting stent use by registry for diabetics (smooth estimate with
95% CI).
Figure 4
Drug-eluting stent use by registry for STEMI (smooth estimate with
95% CI).
Figure 5
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Volume 158, Number 4Adjusted DES use by registry (smooth estimate with 95% CI).Reductions in drug-eluting stent use
Several studies, initially presented at the WCC
conference in September 2006, questioned the safety
of DES linked to the risk of late stent thrombosis.13-17
Subsequent published meta-analyses and large observa-
tional studies have since shown safety and efficacy of
DES without major safety concerns.31-36 This evidence
is particularly strong for “on-label” patients studied in
the pivotal randomized controlled trials, although
further studies have included other important sub-
groups.37-40 It is likely, however, that the controversyand the resultant adverse publicity have influenced
clinical decisions with all registries demonstrating lower
DES use during 2007 following declining use during
2006. Although the WCC conference in September
2006 is seen as an important landmark, our data suggest
reducing DES use commenced prior to this time point.
Thus, the “turn point” for reductions in DES use is
perhaps surprising. A possible explanation is that
physicians were beginning to manage individual cases
of late stent thrombosis in clinical practice; a compli-
cation described as far back as 2004.41,42 Increasing
caution in the use of DES, before the adverse publicity
in September 2006, may have resulted.
By 2007, evidence of selection of patients for DES
was evident within the US-based registry, in particular,
reduced use among patients treated for STEMI. In the
Canadian and UK-based registries, pre-evident factors
effecting selection remained, and in common with the
Mayo Clinic Registry, reductions in patients treated for
STEMI were particularly marked. A possible explana-
tion lies in the importance of dual antiplatelet therapy
in preventing thrombotic events43,44; an assessment of
future patient compliance is particularly challenging
within the acute setting and may discourage the use
of DES.
Implications and determinants of use
The optimum strategy for adoption and use for DES is
not clear. Were DES adopted too early, particularly within
United States, before a full evaluation of the device in
many clinical scenarios? Targeted DES use, for example,
in the United Kingdom and Canada, may make economic
sense. However, “off-label” use was encouraged (eg, very
582 Austin et al
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October 2009long lesions), and many patients for whom benefit and
safety was established were excluded from guidance.
Furthermore, equity of use in systems where the
interventional cardiologist acts as “gatekeeper” can be
compromised.19 Finally, a strict reimbursement system,
such as in Belgium, appears affective in controlling
uptake, limiting overall use and is probably more
equitable. However, this system may be less flexible to
change with the emergence of new data.
Clinically efficacious but expensive new technologies
are frequently developed for use in clinical practice.
Drug-eluting stents are a classic case in point. We have
shown wide international differences in the approach
to DES and varying reductions in use following reports
of late stent thrombosis. These findings raise generic
questions with respect to the determinants of utiliza-
tion which include clinical evidence and its applicabil-
ity to actual practice; public and medical perception,
including the importance of marketing and (adverse)
publicity; the role of national regulatory and rationing
agencies; and the influence and extent of health
service control.Strengths and weaknesses of the study
Our study has provided an overview of international
PCI practice since the introduction of DES. While
international differences in DES use and recent reduc-
tions are often alluded to, no study to date has outlined
this in detail. The comparison of a sample of North
American and European practice is therefore unique in
the current literature. Other strengths include the
comprehensive case ascertainment and collection of
procedural covariates key to clinical decision-making.
Data collected by the registries are broadly consistent
and the majority of relevant clinical details can be
reliably determined. We believe that observations and
discussion of practice influences are germane beyond
the areas studied.
Our study has some weaknesses. The Mayo Clinic as
a major academic centre may not necessarily directly
reflect US practice and includes patients from outside
the local region. As a relatively smaller community of
operators, practice may also change at a more rapid
rate. In addition, a small fraction of total US practice is
represented, with comparatively greater proportions of
UK, Canadian (both approximately 10%), and Belgian
(close to 100%) clinical activity represented. We accept
that this is therefore not a comprehensive survey;
sample proportions from each country vary and that
other practice patterns are possible, even within the
countries studied.
We used registry data to obtain a representation of
actual clinical practice and rely on surrogates such as
stent dimensions. Furthermore, each data set is not
centrally audited, thus we cannot exclude idiosyncrasiesbetween data sets. Despite this, key variables were
defined consistently, and determined from original lesion
and patient records.
Our study has an observational, descriptive design. To
place our findings in context, we drew on previous
literature and identified key external pressures on
clinical practice. Because of this and the complex
nature of the trends identified, much of our results
and discussion are therefore qualitative. As with all
observational studies, we cannot be sure that all relevant
variables are accounted for within the adjusted analysis
and it is not possible to demonstrate causal link between
a given event and change in practice. Segmented time-
series analysis can be used in ecological studies to
identify temporal changes in relation to external events;
however, this approach would have been too simplistic
in this case.
Conclusion
International adoption and use of DES showed wide
variation in this study of PCI practice in four countries.
Reductions in DES use were observed during 2006, but
the timing and nature of this reduction also varied
geographically. A consensus therefore does not exist for
the optimum application of DES in clinical practice,
although influences on stent choice in the “real world”
are multifactorial. These data are a reminder of the gap
that often exists between the goal of evidence-base
medicine and actual clinical practice.Acknowledgements
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